Show simple item record

dc.contributor.author Bursacovschi, Natalia
dc.date.accessioned 2022-02-18T10:07:54Z
dc.date.available 2022-02-18T10:07:54Z
dc.date.issued 2010
dc.identifier.citation BURSACOVSCHI, Natalia. Pulmonary arterial hypertension in scleroderma. In: MedEspera: the 3rd Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2010, p. 44. en_US
dc.identifier.uri http://repository.usmf.md/handle/20.500.12710/20211
dc.description.abstract Systemic sclerosis (SSc) is a rare chronic disease of unknown cause characterized by diffuse fibrosis and degenerative changes in the skin and internal organs. It can cause serious complications in the lungs in two major ways: the pulmonary fibrosis and pulmonary hypertension (PAH). Owing to the fact that lung damage in SSc has a high incidence (70 % in the necropsy studies) and represents the leading cause of death in scleroderma patients, it is required an early systemic evaluation of lung complications in these patients. The objective was to study the particularities of lung complications in patients with SSc. Material and methods This study is based on the surveying of 12 patients with the SSc, aged between 28 and 68 years old, the majority of the patients being females. The diagnosis was established on the bases of the clinical presentation, the laboratory data and the instrumental examination: hemoleucogram, immunological tests (Anti-Scl 70 antibody, Anticentromere antibody), ECG, echocardiography, spirography, chest X-ray, CT of the chest, pulse-oximetry. Results and discussions The lung complications were determined in a big number of patients 83.3 %. PAH was diagnosed in 4 patients: 1 case of severe isolated PAH in a patient with limited form of SSc, and 3 cases of light PAH associated with pulmonary fibrosis. Pulmonary fibrosis without PAH was determined in a half of examined patients. Cor pulmonale was revealed in 2 patients, both of them with PAH. The symptoms of lung damage were non-specific and consisted of shortness of breath from an activity (at 8 patients from 10) and dry cough (at 5 patients from 10). In order to treat the severe PAH was administrated a phosphodiesterase 5 inhibitor (Sildenafil) and a calcium channel blocker (Verapamil) with a good clinical and hemodynamic response. Conclusions: 1. Both the diffuse and the limited subsets of scleroderma patient may develop PAH, but it is more common in patients with limited scleroderma. 2. Symptoms that might indicate PAH are non-specific. 3. Echocardiography is recommended in the annual evaluation of all sclerodermic patients. 4. New effective treatments may improve quality of life and improve long-term outcome. en_US
dc.language.iso en en_US
dc.publisher Nicolae Testemitanu State Medical and Pharmaceutical University en_US
dc.relation.ispartof MedEspera: The 3rd International Medical Congress for Students and Young Doctors, May 19-21, 2010, Chisinau, Republic of Moldova en_US
dc.title Pulmonary arterial hypertension in scleroderma en_US
dc.type Other en_US


Files in this item

This item appears in the following Collection(s)

  • MedEspera 2010
    The 3rd International Medical Congress for Students and Young Doctors, May 19-21, 2010

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics